Short Interest in SciSparc Ltd. (NASDAQ:SPRC) Drops By 56.2%

SciSparc Ltd. (NASDAQ:SPRC) was the recipient of a significant decline in short interest during the month of January. As of January 30th, there was short interest totaling 176,031 shares, a decline of 56.2% from the January 15th total of 401,983 shares. Currently, 5.0% of the shares of the stock are sold short. Based on an average trading volume of 562,920 shares, the short-interest ratio is currently 0.3 days. Based on an average trading volume of 562,920 shares, the short-interest ratio is currently 0.3 days. Currently, 5.0% of the shares of the stock are sold short.

SciSparc Trading Down 0.2%

Shares of SPRC opened at $0.60 on Friday. The stock has a 50 day moving average price of $1.22 and a 200 day moving average price of $2.81. SciSparc has a one year low of $0.58 and a one year high of $11.11.

SciSparc (NASDAQ:SPRC) last posted its quarterly earnings results on Tuesday, November 18th. The company reported ($3.08) earnings per share for the quarter. The company had revenue of $0.23 million for the quarter.

About SciSparc

SciSparc AG is a clinical‐stage medical technology company focused on the development and commercialization of extracorporeal shock wave–based neuromodulation devices. Founded in 2016 and headquartered in Switzerland, the company applies proprietary low‐intensity shock wave technology to noninvasively stimulate neural tissue. SciSparc completed its initial public offering on the NASDAQ in 2021 under the ticker SPRC, securing funding to advance its clinical pipeline.

The company’s lead product, the TR100 system, delivers transcranial shock wave stimulation (tSWS) designed to target areas of the brain associated with motor control and cognitive function.